Form 4: Artiva Biotherapeutics Insider Filing: GC Corp and GC Cell Increase Common Stock Holdings Post-IPO

Yong-Jun Huh, as a director and related to significant shareholders GC Corp and GC Cell Corporation, reports transactions related to the conversion of preferred stock and SAFE agreements into common stock following Artiva Biotherapeutics' IPO.

Summary

• This Form 4 filing details changes in beneficial ownership of Artiva Biotherapeutics, Inc. (ARTV) stock by Yong-Jun Huh, a director.
• The transactions occurred on July 22, 2024, and involve the conversion of preferred stock and simple agreements for future equity (SAFE) into common stock, as well as purchases in the IPO.
• GC Corp. and GC Cell Corporation, entities related to Yong-Jun Huh, acquired significant amounts of common stock through these conversions and IPO participation.
• Specifically, Series A and B Preferred Stock converted into common stock on a one-for-one basis upon the closing of the IPO.
• SAFE agreements totaling $3,000,000 and $2,614,424.28 were converted into common stock at a 15% discount to the IPO price of $12.
• GC Corp. now indirectly beneficially owns 3,306,900 shares of common stock, while GC Cell Corporation indirectly beneficially owns 1,260,512 shares.
• Yong-Jun Huh disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The transactions reflect standard post-IPO adjustments and continued investment by major shareholders, suggesting confidence in the company's prospects.

Positives

• The conversion of preferred stock and SAFE agreements into common stock indicates confidence in Artiva's future prospects following the IPO.
• Significant purchases by GC Corp. and GC Cell Corporation in the IPO suggest strong support from major shareholders.

Future Outlook

The filing does not contain explicit forward-looking statements, but the transactions suggest continued involvement and investment by GC Corp. and GC Cell Corporation in Artiva Biotherapeutics.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their trading activities. The conversion of preferred stock and SAFE agreements is a common occurrence following an IPO.

Comparison to Industry Standards

• Insider transactions are a normal part of the corporate landscape, especially after significant events like IPOs.
• Comparing the size and frequency of these transactions to those of insiders at comparable biotech companies (e.g., Allogene Therapeutics, CRISPR Therapeutics) after their IPOs could provide further context.
• The level of ownership by GC Corp and GC Cell Corporation can be compared to ownership structures of other biotech companies with significant corporate backing, such as Roche's stake in Genentech.

Related Party Transactions

• The transactions involve GC Corp. and GC Cell Corporation, which are related parties due to Yong-Jun Huh's role as Chief Executive Officer of GC Corp.

Stakeholder Impact

• The increased holdings by GC Corp. and GC Cell Corporation could be viewed positively by shareholders, signaling confidence in the company's future.
• The conversion of preferred stock and SAFE agreements dilutes existing shareholders to a small degree.

Key Dates